Metformin Biohackers Skip the Urgency AIDS Activists Had

A growing cohort of self-quantifying biohackers have begun dosing themselves with metformin, a diabetes medication, based on the premise that it extends lifespan.

They track biomarkers, publish results to blogs and forums. Treat their own bodies as laboratories — but the peer-reviewed evidence does not yet support this use in healthy people. Animal studies show promise and human trials remain years from completion. The biohackers proceed anyway, reasoning that waiting for formal approval means gambling with years they might not have.

This echoes the AIDS activist model of the 1980s and 1990s. When protease inhibitors showed preliminary promise against HIV, patients with AIDS did not wait for FDA approval — they synthesized their own from underground chemists, imported them from Mexico, shared dosing protocols across phone trees and early internet forums.

They ran their own trials and tracked their own T-cell counts. They published their findings in ACT UP newsletters and forced the FDA's hand by overwhelming evidence that informal channels were working better than official ones could manage. The FDA responded by creating accelerated approval pathways and accepting surrogate endpoints. Intermediate markers like CD4 counts instead of waiting for final proof that patients lived longer. By 1996, protease inhibitors had transformed AIDS from a death sentence into a manageable chronic condition.

The structural mechanism was urgent necessity creating justified distrust. Patients faced imminent death and official institutions had failed them systematically. So the underground trial became not just ethically defensible but morally obvious. Metformin biohackers occupy this structure without the urgency. They face no deadline and distrust institutions out of philosophical preference rather than institutional abandonment. They have positioned themselves as ahead of the curve rather than abandoned by the system, replicating the activist form but jettisoning the disease urgency and community accountability that forced rigorous self-documentation. And so they have mistaken the shape of evidence-making for evidence itself.

Watch for when the first large-scale adverse event emerges from a biohacker community. The AIDS activists had T-cell counts. Objective measures that revealed when a protocol failed. The metformin cohort has subjective vitality markers and biomarkers that correlate with longevity outcomes nobody has lived long enough to verify. That mistake compounds in any domain where you cannot tell whether your experiment worked until years after you stop running it.